HPC Offered for PRESERVE Expansion
ConditionBone Marrow Transplant (BMT)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12-80
SponsorOssium Health, Inc.
About this trial
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Patients undergoing allogenic bone marrow transplant
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
Other interventionThe HOPE Program does not include any investigational drugs. The medicines and procedures in this program are standard of care for a transplant. Bone marrow cells from a deceased organ and tissue donor for use in your transplant is the only product offered to you by Ossium Health.
Treatment groups
10 Participants
are divided into 1 treatment groupGroup A: Ossium HPC, Marrow1 intervention
Trial outcomes
Primary outcomes
1
Neutrophil engraftment
1\. To determine cumulative incidences of neutrophil engraftment (ANC ≥500/µL for 3 consecutive values)
Time frame
28 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov